These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36950274)

  • 1. A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors.
    Donadio MD; Brito ÂB; Riechelmann RP
    Ther Adv Med Oncol; 2023; 15():17588359231156218. PubMed ID: 36950274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
    Xu JX; Wu DH; Ying LW; Hu HG
    World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
    Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.
    Liu AJ; Ueberroth BE; McGarrah PW; Buckner Petty SA; Kendi AT; Starr J; Hobday TJ; Halfdanarson TR; Sonbol MB
    Oncologist; 2021 May; 26(5):383-388. PubMed ID: 33496040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ; Whitman J; Paciorek A; Le BK; Nakakura EK; Behr SC; Joseph N; Zhang L; Hope TA; Bergsland EK
    J Neuroendocrinol; 2023 Apr; 35(4):e13260. PubMed ID: 37002881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Well differentiated grade 3 gastroenteropancreatic neuroendocrine tumors:new insights into diagnosis and therapeutic strategy].
    Fan ZY; Shi M; Yang J; Li YZ; Su P; Wang X; Zhan HX
    Zhonghua Wai Ke Za Zhi; 2021 Aug; 59(8):704-710. PubMed ID: 34192864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
    Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis.
    Ziogas IA; Tasoudis PT; Borbon LC; Sherman SK; Breheny PJ; Chandrasekharan C; Dillon JS; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2023 Jan; 30(1):148-160. PubMed ID: 36227392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
    Sorbye H; Kong G; Grozinsky-Glasberg S
    Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors.
    Graf A; Welch J; Bansal R; Mandl A; Parekh VI; Cochran C; Levy E; Nilubol N; Patel D; Sadowski S; Jha S; Agarwal SK; Millo C; Blau JE; Simonds WF; Weinstein LS; Del Rivero J
    J Endocr Soc; 2022 Oct; 6(10):bvac122. PubMed ID: 36111275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
    Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
    J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.
    Zappi A; Persano I; Galvani L; Parlagreco E; Andrini E; Campana D; Brizzi MP; Lamberti G; La Salvia A
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
    Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
    Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.